ARS Pharmaceuticals (SPRY) Leases (2021 - 2025)
Historic Leases for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to $1.4 million.
- ARS Pharmaceuticals' Leases rose 146413.04% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 146413.04%. This contributed to the annual value of $37000.0 for FY2024, which is 8520.0% down from last year.
- ARS Pharmaceuticals' Leases amounted to $1.4 million in Q3 2025, which was up 146413.04% from $1.6 million recorded in Q2 2025.
- Over the past 5 years, ARS Pharmaceuticals' Leases peaked at $5.0 million during Q3 2021, and registered a low of $37000.0 during Q4 2024.
- Moreover, its 5-year median value for Leases was $421500.0 (2022), whereas its average is $1.3 million.
- Its Leases has fluctuated over the past 5 years, first tumbled by 9112.4% in 2023, then skyrocketed by 146413.04% in 2025.
- Quarter analysis of 5 years shows ARS Pharmaceuticals' Leases stood at $621000.0 in 2021, then fell by 28.34% to $445000.0 in 2022, then crashed by 43.82% to $250000.0 in 2023, then plummeted by 85.2% to $37000.0 in 2024, then soared by 3789.19% to $1.4 million in 2025.
- Its Leases was $1.4 million in Q3 2025, compared to $1.6 million in Q2 2025 and $72000.0 in Q1 2025.